MOS Translation Group – Four Seasons

ON TUESDAY, the U.S. Food and Drug Administration expanded the emergency use authorization for Pfizer’s COVID-19 vaccine, authorizing booster shots for young children ages 5 to 11 for at least five months after receiving a second dose; survive the News reported on May 17.

FDA Commissioner Robert M. Califf said in a statement that while COVID-19 tends to be milder in children than in adults to a large extent, with the variant Omicron, more children develop the disease and are hospitalized, and children may also experience longer-term effects, even after the initial mild illness. Vaccination can help them avoid potentially serious consequences, such as hospitalization and death.

Last December, the FDA approved Pfizer’s Covid booster shot for 16 and 17-year-olds. On January 3 of this year, the FDA authorized the use of a single booster shot of Pfizer Covid-19 for children ages 12 to 15.

The CDC Vaccine Advisory Panel previously held an online meeting late last year to discuss concerns about the occurrence of myocarditis in young children, noting that the U.S. Vaccine Adverse Event Reporting System (VAERS) has received several records of severe heart disease in children ages 5-11.

Edited and posted by: Kayla J.

For more information, please follow us at:
New York MOS Himalaya |GTV
New York MOS Himalaya |MOS TALK
New York MOS Himalaya | GETTR
New York MOS Himalaya |YouTube
Free to Join New York MOS Himalaya | Discord